LVW Advisors LLC Sells 576 Shares of Humana Inc. (NYSE:HUM)

LVW Advisors LLC lowered its position in Humana Inc. (NYSE:HUM) by 33.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,123 shares of the insurance provider’s stock after selling 576 shares during the quarter. LVW Advisors LLC’s holdings in Humana were worth $389,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Rakuten Securities Inc. bought a new position in Humana in the fourth quarter worth approximately $25,000. Gradient Investments LLC grew its stake in Humana by 200.0% in the fourth quarter. Gradient Investments LLC now owns 60 shares of the insurance provider’s stock worth $27,000 after purchasing an additional 40 shares in the last quarter. Cetera Trust Company N.A bought a new position in Humana in the fourth quarter worth approximately $28,000. Private Wealth Management Group LLC bought a new position in Humana in the fourth quarter worth approximately $32,000. Finally, Carolinas Wealth Consulting LLC grew its stake in Humana by 274.1% in the fourth quarter. Carolinas Wealth Consulting LLC now owns 101 shares of the insurance provider’s stock worth $46,000 after purchasing an additional 74 shares in the last quarter. Institutional investors own 92.38% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on HUM. Barclays lowered their target price on Humana from $356.00 to $310.00 and set an “equal weight” rating for the company in a report on Tuesday, April 2nd. The Goldman Sachs Group decreased their price objective on Humana from $450.00 to $385.00 and set a “buy” rating for the company in a report on Wednesday, April 3rd. TD Cowen decreased their price objective on Humana from $427.00 to $396.00 and set a “buy” rating for the company in a report on Tuesday, April 2nd. Wells Fargo & Company decreased their price objective on Humana from $413.00 to $350.00 and set an “overweight” rating for the company in a report on Monday, April 8th. Finally, Argus lowered Humana from a “buy” rating to a “hold” rating in a report on Wednesday, March 13th. Fourteen investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $409.55.

Humana Trading Up 2.9 %

Shares of Humana stock opened at $373.65 on Monday. The firm has a market capitalization of $45.02 billion, a PE ratio of 23.27, a P/E/G ratio of 2.16 and a beta of 0.51. Humana Inc. has a twelve month low of $298.61 and a twelve month high of $530.54. The firm’s 50-day moving average price is $343.78 and its 200 day moving average price is $351.23. The company has a current ratio of 1.67, a quick ratio of 1.67 and a debt-to-equity ratio of 0.77.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share for the quarter, beating analysts’ consensus estimates of $6.12 by $1.11. Humana had a net margin of 1.82% and a return on equity of 17.76%. The firm had revenue of $29.61 billion for the quarter, compared to analyst estimates of $28.52 billion. During the same period last year, the company posted $9.38 EPS. Humana’s quarterly revenue was up 10.7% compared to the same quarter last year. On average, sell-side analysts predict that Humana Inc. will post 16.27 EPS for the current fiscal year.

Humana Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be paid a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 0.95%. The ex-dividend date of this dividend is Friday, June 28th. Humana’s dividend payout ratio (DPR) is 22.04%.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.